“Pfizer's fourth-quarter results were a little better than our optimistic expectations and show the company is in very, very good condition with its biggest drugs going strong.”
“That may be below the bullish $5 billion or $10 billion annual forecasts that some analysts had originally made for Viagra, but $2 billion is an impressive reward for Pfizer.”
